How mRNA is powering a personalized vaccine revolution.
作者信息
May Mike
出版信息
Nat Med. 2024 Aug;30(8):2097-2098. doi: 10.1038/d41591-024-00052-y.
PMID:39009892
Abstract
摘要
相似文献
1
How mRNA is powering a personalized vaccine revolution.信使核糖核酸如何推动个性化疫苗革命。
Nat Med. 2024 Aug;30(8):2097-2098. doi: 10.1038/d41591-024-00052-y.
2
A network analysis of COVID-19 mRNA vaccine patents.新冠病毒mRNA疫苗专利的网络分析
Nat Biotechnol. 2021 May;39(5):546-548. doi: 10.1038/s41587-021-00912-9.
3
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.有或无前新冠病毒感染启动的情况下，SARS-CoV-2疫苗BNT162b2的抗体依赖性中和能力
J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
4
mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.慢性淋巴细胞白血病患者接种新型冠状病毒 mRNA 疫苗：一项系统评价与荟萃分析。
Eur J Haematol. 2022 Mar;108(3):264-267. doi: 10.1111/ejh.13729. Epub 2021 Dec 13.
5
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.成年人接种 COVID-19 mRNA 疫苗后出现急性心肌炎。
JAMA Intern Med. 2021 Dec 1;181(12):1668-1670. doi: 10.1001/jamainternmed.2021.5511.
6
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.单剂 mRNA 疫苗为 hACE2 转基因小鼠提供了针对 SARS-CoV-2 的长期保护。
Nat Commun. 2021 Feb 3;12(1):776. doi: 10.1038/s41467-021-21037-2.
7
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
8
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.SARS-CoV-2 感染受试者对 BNT162b2 mRNA COVID-19 疫苗的抗体反应。
Viruses. 2021 Mar 5;13(3):422. doi: 10.3390/v13030422.
9
Vaccines against COVID-19.针对新型冠状病毒肺炎的疫苗。
Anaesth Crit Care Pain Med. 2020 Dec;39(6):703-705. doi: 10.1016/j.accpm.2020.10.006. Epub 2020 Oct 20.
10
Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的进化：对谱系和疫苗有效性的预测
Travel Med Infect Dis. 2021 Mar-Apr;40:101983. doi: 10.1016/j.tmaid.2021.101983. Epub 2021 Feb 4.
引用本文的文献
1
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle.mRNA产品全生命周期开发、监管与应用的考量因素
Vaccines (Basel). 2025 Apr 28;13(5):473. doi: 10.3390/vaccines13050473.
2
Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy.用于癌症免疫治疗的mRNA疫苗设计中的计算生物学与人工智能
Front Cell Infect Microbiol. 2025 Jan 20;14:1501010. doi: 10.3389/fcimb.2024.1501010. eCollection 2024.
3
Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.免疫调节纳米颗粒激活细胞毒性 T 细胞，增强癌症免疫疗法的效果。
Nanoscale. 2024 Oct 3;16(38):17699-17722. doi: 10.1039/d4nr01780c.
Zotero 插件